<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561687</url>
  </required_header>
  <id_info>
    <org_study_id>98-01-49-21547</org_study_id>
    <nct_id>NCT04561687</nct_id>
  </id_info>
  <brief_title>Comparison of Montelukast and Azelastine in Treatment of Moderate to Severe Allergic Rhinitis</brief_title>
  <official_title>Comparison of Montelukast and Azelastine in Treatment of Moderate to Severe Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of Montelukast and Azelastine In treatment of Allergic Rhinitis Allergic intent is&#xD;
      one of the most common diseases of the respiratory system that has a devastating effect on&#xD;
      the quality of life. The importance of studying this disease can be seen from the high&#xD;
      prevalence of this diseas. In addition to the high prevalence, due to the reducing effect of&#xD;
      this disease on the economy and academic performance of patients, a great burden is imposed&#xD;
      by this disease on the country's health care system.Also finding the best treatment of&#xD;
      allergic can help to control of Asthma if exists concurrently.&#xD;
&#xD;
      Inflammation of the nasal mucosa following the release of IgE can be shown as symptoms of&#xD;
      runny nose, sneezing, nasal congestion.Many studies have been done in the field of allergic&#xD;
      rhinitis to increase the cost-effectiveness of treatment of this complication. Among the&#xD;
      treatments for this disease is the use of antihistamine nasal sprays such as Azelastine.&#xD;
      Combination therapies such as combining Mometason furoate or fluticasone with Azelastine or&#xD;
      Montelukast can also be mentioned. However, there is still a long way to go to find the best&#xD;
      drug combination to reduce the economic and human costs to the global health system. Due to&#xD;
      the high prevalence of allergic diseases such as allergic rhinitis, finding the best&#xD;
      treatment or management of such diseases plays an important role in improving the quality of&#xD;
      life and reducing the economic burden on society.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 16, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Sino-Nasal Outcome Test scores (SNOT-22)</measure>
    <time_frame>Baseline,month1,month3</time_frame>
    <description>Change in Sino-Nasal Outcome Test scores (SNOT-22) scores pre- and post-treatment. The Sino-Nasal Outcome Test asks subjects to rate how &quot;bad&quot; their rhinosinusitis by using a 0-5 point scale with 0=no problem, 1=very mild problem, 2=mild or slight problem, 3=moderate problem, 4=severe problem, 5=problem as bad as it can be.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Azelastine and Nasal Budesonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Spray nasal Azelastine 1puff daily for 6-12years old patients and 2puff for older</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast and Nasal budesonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Montelukast 5mg 6-14years old and 10mg for older</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nasal Budesonide and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>Montelukast and nasal budesonide</description>
    <arm_group_label>Montelukast and Nasal budesonide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azelastine</intervention_name>
    <description>Azelastine and nasal budesonide</description>
    <arm_group_label>Azelastine and Nasal Budesonide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>To all groups</description>
    <arm_group_label>Azelastine and Nasal Budesonide</arm_group_label>
    <arm_group_label>Montelukast and Nasal budesonide</arm_group_label>
    <arm_group_label>Nasal Budesonide and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo and nasal budesonide</description>
    <arm_group_label>Nasal Budesonide and Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 6-50years&#xD;
&#xD;
          -  Moderate to severe allergic rhinitis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under any treatment&#xD;
&#xD;
               -  Drug sensitivity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nasrin Mortazavi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University of Medical Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nasrin Mortazavi Far</last_name>
    <phone>989195774656</phone>
    <email>nasrinmortazavi@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shiraz University of Medical Science</name>
      <address>
        <city>Shiraz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Nasrin Mortazavi Far</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelastine</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

